Parkinson's disease pipeline

Feb 24, 2025

Parkinson’s disease, a progressive neurodegenerative disorder, is emerging as a significant health challenge in the United States and globally, primarily due to an aging population. This condition, characterized by motor symptoms such as tremors, muscle rigidity, and slowed movement, along with numerous non-motor s...

Dec 31, 2024

Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment of Parkinson’s disease. Unlike traditional treatments that focus on managing symptoms, Risvodetinib targets the underlying biological mechanisms driving disease progression. Risvo...

Dec 23, 2024

Parkinson's disease is a progressive neurodegenerative disorder that primarily affects movement, causing tremors, stiffness, and balance problems. The condition develops when nerve cells in the brain that produce dopamine, a chemical that helps control muscle movements, become damaged or die. As one of the most com...

Nov 25, 2024

Cell and gene therapies are transforming Parkinson's treatment, bringing new hope to patients who previously had few options. While traditional approaches focus on symptom management, these advanced therapies target the underlying causes of the disease. By introducing healthy cells or repairing faulty genes, resear...